Northern Biologics (preclinical programs) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Northern Biologics (preclinical programs) General Information

Description

Two preclinical programs developed by Canadian biotech Northern Biologics. The program has aspects of what's known as the tumor microenvironment: stroma, or connective tissue made up of different cell types, and myeloid cells.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 101 College Street
  • PMCRT 15-701
  • Toronto, Ontario M5G 1L7
  • Canada
Primary Industry
Biotechnology
Other Industries
Buildings and Property
Acquirer
Boehringer Ingelheim
Corporate Office
  • 101 College Street
  • PMCRT 15-701
  • Toronto, Ontario M5G 1L7
  • Canada

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Northern Biologics (preclinical programs) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Northern Biologics (preclinical programs)‘s full profile, request access.

Request a free trial

Northern Biologics (preclinical programs) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Northern Biologics (preclinical programs)‘s full profile, request access.

Request a free trial

Northern Biologics (preclinical programs) FAQs

  • Where is Northern Biologics (preclinical programs) headquartered?

    Northern Biologics (preclinical programs) is headquartered in Toronto, Canada.

  • What industry is Northern Biologics (preclinical programs) in?

    Northern Biologics (preclinical programs)’s primary industry is Biotechnology.

  • Is Northern Biologics (preclinical programs) a private or public company?

    Northern Biologics (preclinical programs) is a Private company.

  • What is Northern Biologics (preclinical programs)’s current revenue?

    The current revenue for Northern Biologics (preclinical programs) is .

  • Who are Northern Biologics (preclinical programs)’s investors?

    Northern Biologics has invested in Northern Biologics (preclinical programs).

  • When was Northern Biologics (preclinical programs) acquired?

    Northern Biologics (preclinical programs) was acquired on 14-May-2020.

  • Who acquired Northern Biologics (preclinical programs)?

    Northern Biologics (preclinical programs) was acquired by Boehringer Ingelheim.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »